

# Magnus Ingelman-Sundberg

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5867950/publications.pdf>

Version: 2024-02-01

367  
papers

28,387  
citations

3721

89  
h-index

9553

142  
g-index

392  
all docs

392  
docs citations

392  
times ranked

21107  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, 116, 496-526.		990
2	Dietary long-chain nâˆ’3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition, 2004, 79, 935-945.	2.2	813
3	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology and Therapeutics, 2006, 79, 103-113.	2.3	620
4	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends in Pharmacological Sciences, 2004, 25, 193-200.	4.0	579
5	Pharmacogenomics and Individualized Drug Therapy. Annual Review of Medicine, 2006, 57, 119-137.	5.0	576
6	Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology, 1998, 27, 128-133.	3.6	573
7	Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochemical Pharmacology, 1989, 38, 1313-1319.	2.0	508
8	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Scientific Reports, 2016, 6, 25187.	1.6	502
9	Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends in Pharmacological Sciences, 1999, 20, 342-349.	4.0	470
10	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (<i>CYP</i>) Allele Nomenclature Database. Clinical Pharmacology and Therapeutics, 2018, 103, 399-401.	2.3	335
11	Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 89-104.	1.4	288
12	Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5â€™-Upstream Regulatory Region. Biochemical and Biophysical Research Communications, 1999, 259, 201-205.	1.0	280
13	Hydroxylation of salicylate as an assay for hydroxyl radicals: A cautionary note. Free Radical Biology and Medicine, 1991, 10, 439-441.	1.3	259
14	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 2002, 23, 1343-1350.	1.3	250
15	Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish Population. Biochemical and Biophysical Research Communications, 1999, 254, 628-631.	1.0	239
16	Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. European Journal of Clinical Pharmacology, 2007, 63, 537-546.	0.8	222
17	Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. Biochemical and Biophysical Research Communications, 1986, 134, 1215-1222.	1.0	221
18	Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol, 1993, 10, 447-452.	0.8	219

#	ARTICLE	IF	CITATIONS
19	Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. <i>Toxicological Sciences</i> , 2018, 162, 655-666.	1.4	219
20	COMPARATIVE ANALYSIS OF CYP3A EXPRESSION IN HUMAN LIVER SUGGESTS ONLY A MINOR ROLE FOR CYP3A5 IN DRUG METABOLISM. <i>Drug Metabolism and Disposition</i> , 2003, 31, 755-761.	1.7	213
21	Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450. <i>Toxicological Sciences</i> , 2011, 120, 1-13.	1.4	213
22	Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 187-191.	5.7	201
23	3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. <i>Toxicological Sciences</i> , 2013, 133, 67-78.	1.4	197
24	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. <i>Chemical Research in Toxicology</i> , 2016, 29, 1936-1955.	1.7	196
25	Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. <i>Genetics in Medicine</i> , 2017, 19, 20-29.	1.1	194
26	Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. <i>FEBS Letters</i> , 1985, 183, 265-269.	1.3	191
27	A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity. <i>British Journal of Clinical Pharmacology</i> , 1996, 42, 713-719.	1.1	189
28	Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 12-17.	2.3	186
29	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 447-450.	1.1	186
30	Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. <i>FEBS Letters</i> , 1999, 448, 105-110.	1.3	182
31	Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver. <i>Biochemical and Biophysical Research Communications</i> , 1988, 157, 55-60.	1.0	174
32	Sodium periodate, sodium chlorite, organic hydroperoxides, and H <sub>2</sub> O <sub>2</sub> as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome P-450. <i>Biochemical and Biophysical Research Communications</i> , 1975, 66, 209-216.	1.0	173
33	Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 1349-1355.	1.0	167
34	Integrating rare genetic variants into pharmacogenetic drug response predictions. <i>Human Genomics</i> , 2018, 12, 26.	1.4	166
35	Metabolism: A Bottleneck in <i>In Vitro</i> Toxicological Test Development. <i>ATLA Alternatives To Laboratory Animals</i> , 2006, 34, 49-84.	0.7	161
36	Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2. <i>Free Radical Biology and Medicine</i> , 2015, 78, 202-212.	1.3	161

#	ARTICLE	IF	CITATIONS
37	Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. <i>Biochemical and Biophysical Research Communications</i> , 1988, 150, 436-443.	1.0	159
38	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. <i>FEBS Letters</i> , 1999, 460, 321-327.	1.3	158
39	Genetic Polymorphism of CYP1A2 in Ethiopians Affecting Induction and Expression: Characterization of Novel Haplotypes with Single-Nucleotide Polymorphisms in Intron 1. <i>Molecular Pharmacology</i> , 2003, 64, 659-669.	1.0	158
40	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 131-148.	21.5	153
41	Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1528-1538.	1.7	148
42	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 191-198.	0.7	145
43	Identification of a Single Nucleotide Polymorphism in the TATA Box of the CYP2A6 Gene: Impairment of Its Promoter Activity. <i>Biochemical and Biophysical Research Communications</i> , 2001, 284, 455-460.	1.0	144
44	Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. <i>Biochemical Pharmacology</i> , 1991, 41, 1895-1902.	2.0	143
45	Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. <i>Gene</i> , 1999, 226, 327-338.	1.0	141
46	Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury. <i>Drug Metabolism and Disposition</i> , 2017, 45, 419-429.	1.7	141
47	CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2,451 cases and 3,358 controls. <i>International Journal of Cancer</i> , 2003, 104, 650-657.	2.3	140
48	Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. <i>Toxicological Sciences</i> , 2018, 163, 655-665.	1.4	140
49	Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. <i>American Journal of Psychiatry</i> , 2018, 175, 463-470.	4.0	136
50	A Combination of Mutations in the CYP2D6*17 (CYP2D6Z) Allele Causes Alterations in Enzyme Function. <i>Molecular Pharmacology</i> , 1997, 52, 1034-1040.	1.0	134
51	Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. <i>FEBS Letters</i> , 1998, 438, 201-205.	1.3	129
52	Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 767-774.	1.1	129
53	Epigenetic mechanisms of importance for drug treatment. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 384-396.	4.0	129
54	Genetic variation in the human cytochrome P450 supergene family. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 584-594.	0.7	127

#	ARTICLE	IF	CITATIONS
55	Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions. <i>New England Journal of Medicine</i> , 2008, 358, 637-639.	13.9	125
56	Genetic and epigenetic regulation of gene expression in fetal and adult human livers. <i>BMC Genomics</i> , 2014, 15, 860.	1.2	124
57	Differential rates of metabolic activation and detoxication of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by different cytochrome P450 enzymes. <i>Carcinogenesis</i> , 1990, 11, 489-492.	1.3	121
58	Functional Analysis of Six Different Polymorphic CYP1B1 Enzyme Variants Found in an Ethiopian Population. <i>Molecular Pharmacology</i> , 2002, 61, 586-594.	1.0	120
59	Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. <i>FASEB Journal</i> , 2017, 31, 2696-2708.	0.2	119
60	Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. <i>Scientific Reports</i> , 2016, 6, 35434.	1.6	118
61	Epigenomics and Interindividual Differences in Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 727-736.	2.3	114
62	Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 418-426.	3.7	113
63	Characterization of a Human Glutathione S-Transferase $\gamma$ Cluster Containing a Duplicated GSTM1 Gene that Causes Ultrarapid Enzyme Activity. <i>Molecular Pharmacology</i> , 1997, 52, 958-965.	1.0	112
64	Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. <i>Hepatology</i> , 1999, 29, 1503-1510.	3.6	112
65	The Effect of Ethanol-Induced Cytochrome p450E1 on the Inhibition of Proteasome Activity by Alcohol. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 23-29.	1.0	112
66	The human genome project and novel aspects of cytochrome 450 research. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 52-56.	1.3	111
67	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. <i>Human Genetics</i> , 2010, 127, 1-17.	1.8	110
68	The Involvement of Cytochrome P-450 in Hepatic Microsomal Steroid Hydroxylation Reactions Supported by Sodium Periodate, Sodium Chlorite, and Organic Hydroperoxides. <i>FEBS Journal</i> , 1976, 61, 43-52.	0.2	109
69	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. <i>Scientific Reports</i> , 2018, 8, 14297.	1.6	108
70	Zonation of cytochrome P450 isozyme expression and induction in rat liver. <i>FEBS Journal</i> , 1992, 204, 407-412.	0.2	107
71	Signal Transduction-mediated Activation of the Aryl Hydrocarbon Receptor in Rat Hepatoma H4IIE Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 31755-31763.	1.6	106
72	Pharmacogenomic Biomarkers for Improved Drug Therapy—Recent Progress and Future Developments. <i>AAPS Journal</i> , 2018, 20, 4.	2.2	106

#	ARTICLE	IF	CITATIONS
73	Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail ( <i>Colinus virginianus</i> ) by ergosterol biosynthesis inhibiting fungicides (EBIFs). <i>Biochemical Pharmacology</i> , 1994, 48, 1953-1965.	2.0	105
74	Identification and Tissue Distribution of the Novel Human Cytochrome P450 2S1 (CYP2S1). <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 529-535.	1.0	105
75	Pharmacoeigenetics: Its Role in Interindividual Differences in Drug Response. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 426-430.	2.3	105
76	Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. <i>Journal of Biotechnology</i> , 2010, 145, 284-294.	1.9	105
77	PCR-based genotyping for duplicated and deleted CYP2D6 genes. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 351-355.	5.7	103
78	Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. <i>Hepatology</i> , 2016, 64, 1743-1756.	3.6	100
79	Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 441-447.	5.7	98
80	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). <i>Cancer Causes and Control</i> , 2003, 14, 339-346.	0.8	98
81	Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 451-458.	1.0	98
82	Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 339-349.	2.3	98
83	3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. <i>Biotechnology Journal</i> , 2019, 14, e1800347.	1.8	97
84	Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. <i>Cellular Signalling</i> , 2005, 17, 39-48.	1.7	96
85	Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. <i>Free Radical Biology and Medicine</i> , 2005, 39, 619-630.	1.3	96
86	Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 65-82.	4.2	95
87	Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. <i>Human Mutation</i> , 2002, 20, 275-283.	1.1	94
88	The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. <i>Journal of Hepatology</i> , 2009, 50, 572-583.	1.8	94
89	Ethanol and Oxidative Stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	1.4	93
90	Novel extrahepatic cytochrome P450s. <i>Toxicology and Applied Pharmacology</i> , 2005, 207, 57-61.	1.3	93

#	ARTICLE	IF	CITATIONS
91	Phenotypeâ€“genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 299-305.	1.0	93
92	GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES. <i>Drug Metabolism Reviews</i> , 1999, 31, 467-487.	1.5	92
93	Polymorphism of cytochrome P450 and xenobiotic toxicity. <i>Toxicology</i> , 2002, 181-182, 447-452.	2.0	92
94	Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. <i>Biochemical Pharmacology</i> , 2007, 74, 496-503.	2.0	92
95	Pharmacogenomic biomarkers: new tools in current and future drug therapy. <i>Trends in Pharmacological Sciences</i> , 2011, 32, 72-81.	4.0	91
96	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. <i>JAMA Psychiatry</i> , 2021, 78, 270.	6.0	91
97	Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1). <i>Biochemical and Biophysical Research Communications</i> , 1991, 179, 689-694.	1.0	90
98	CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8221.	1.8	90
99	Lipid Peroxidation, CYP2E1 and Arachidonic Acid Metabolism in Alcoholic Liver Disease in Rats. <i>Journal of Nutrition</i> , 1997, 127, 907S-911S.	1.3	87
100	CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 625-631.	0.7	87
101	Long-Term Chronic Toxicity Testing Using Human Pluripotent Stem Cellâ€“Derived Hepatocytes. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1401-1406.	1.7	87
102	Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 656-661.	2.3	86
103	Zonated expression of cytokines in rat liver: Effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. <i>Hepatology</i> , 1998, 27, 1304-1310.	3.6	86
104	Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. , 1999, 81, 325-329.		86
105	A stress-inducible rat liver endoplasmic reticulum protein, ERp29. <i>FEBS Journal</i> , 1998, 251, 304-313.	0.2	85
106	Structural and Functional Characterization of the 5â€“Flanking Region of the Rat and Human Cytochrome P450 2E1 Genes: Identification of a Polymorphic Repeat in the Human Gene. <i>Biochemical and Biophysical Research Communications</i> , 1999, 263, 286-293.	1.0	85
107	A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. <i>Archives of Toxicology</i> , 2017, 91, 1385-1400.	1.9	85
108	Cytochrome b5 as electron donor to rabbit liver cytochrome P-450LM2 in reconstituted phospholipid vesicles. <i>Biochemical and Biophysical Research Communications</i> , 1980, 97, 582-589.	1.0	84

#	ARTICLE	IF	CITATIONS
109	3â€²-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 491-497.	1.0	84
110	Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. <i>Biochemical and Biophysical Research Communications</i> , 1990, 173, 331-338.	1.0	83
111	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. , 2019, 197, 122-152.		83
112	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , 2019, 9, 11585.	1.6	82
113	Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. <i>Pharmacogenetics and Genomics</i> , 2002, 12, 375-383.	5.7	81
114	Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 359-367.	0.7	81
115	Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database. <i>Methods in Molecular Biology</i> , 2013, 987, 251-259.	0.4	78
116	Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 417-427.	5.7	77
117	COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1093-1102.	1.7	77
118	Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. <i>Biochemical Pharmacology</i> , 2004, 67, 1389-1397.	2.0	77
119	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1199-1205.	0.8	75
120	Acetone-regulated synthesis and degradation of cytochrome P450E2 and cytochrome P450B1 in rat liver. <i>FEBS Journal</i> , 1991, 198, 383-389.	0.2	74
121	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. <i>Frontiers in Psychiatry</i> , 2020, 11, 94.	1.3	74
122	Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbonyl tetrachloride reduction and NADPH oxidase activity. <i>Biochemical Pharmacology</i> , 1989, 38, 689-693.	2.0	73
123	The African-specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 77-88.	2.3	73
124	Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. <i>Toxicological Sciences</i> , 2015, 147, 412-424.	1.4	73
125	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1714.	1.8	73
126	Development of the <sc>PG</sc>â€œPassport: A Panel of Actionable Germline Genetic Variants for Preâ€œemptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 866-873.	2.3	73



#	ARTICLE	IF	CITATIONS
127	Identification of CYP4F8 in Human Seminal Vesicles as a Prominent 19-Hydroxylase of Prostaglandin Endoperoxides. <i>Journal of Biological Chemistry</i> , 2000, 275, 21844-21849.	1.6	72
128	Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. <i>Carcinogenesis</i> , 2003, 24, 1533-1539.	1.3	69
129	Different Structural Requirements of the Ligand Binding Domain of the Aryl Hydrocarbon Receptor for High- and Low-Affinity Ligand Binding and Receptor Activation. <i>Molecular Pharmacology</i> , 2004, 65, 416-425.	1.0	69
130	<i>CYP2C19</i> genotype predicts steady state escitalopram concentration in GENDEP. <i>Journal of Psychopharmacology</i> , 2012, 26, 398-407.	2.0	69
131	Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 397-406.	0.8	69
132	Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. <i>Tissue Engineering - Part C: Methods</i> , 2018, 24, 534-545.	1.1	69
133	Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. <i>Biomarkers</i> , 2002, 7, 230-241.	0.9	68
134	Mechanisms of Down-Regulation of CYP2E1 Expression by Inflammatory Cytokines in Rat Hepatoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 1048-1054.	1.3	68
135	Potential Role of Epigenetic Mechanisms in the Regulation of Drug Metabolism and Transport. <i>Drug Metabolism and Disposition</i> , 2013, 41, 1725-1731.	1.7	68
136	AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 217-226.	3.3	68
137	Autoantibodies against Cytochromes P-450E1 and P-450A in Alcoholics. <i>Molecular Pharmacology</i> , 1999, 55, 223-233.	1.0	66
138	Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. <i>Journal of Hepatology</i> , 2000, 32, 900-910.	1.8	66
139	Human Embryonic Stem Cell Derived Hepatocyte-Like Cells as a Tool for In Vitro Hazard Assessment of Chemical Carcinogenicity. <i>Toxicological Sciences</i> , 2011, 124, 278-290.	1.4	66
140	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. <i>Genetics in Medicine</i> , 2018, 20, 622-629.	1.1	66
141	Demonstration of a cytochrome P-450-dependent steroid 15 $\beta$ -hydroxylase in <i>Bacillus megaterium</i> . <i>Biochemical and Biophysical Research Communications</i> , 1975, 66, 1414-1423.	1.0	65
142	Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH $\alpha$ -cytochrome P450 reductase. <i>Biochemical Journal</i> , 1999, 340, 453-458.	1.7	63
143	Genetic variability in susceptibility and response to toxicants. <i>Toxicology Letters</i> , 2001, 120, 259-268.	0.4	63
144	Expression of CYP2W1 in colon tumors: regulation by gene methylation. <i>Pharmacogenomics</i> , 2007, 8, 1315-1325.	0.6	63

#	ARTICLE	IF	CITATIONS
145	Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. <i>Biochemical and Biophysical Research Communications</i> , 2010, 396, 90-94.	1.0	63
146	Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 902-907.	2.3	63
147	Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. <i>Human Mutation</i> , 2008, 29, 1147-1153.	1.1	62
148	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1240-1255.	2.3	62
149	Molecular Basis for the Transport of Cytochrome P450 2E1 to the Plasma Membrane. <i>Journal of Biological Chemistry</i> , 2000, 275, 17130-17135.	1.6	61
150	Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. <i>Genome Biology</i> , 2013, 14, R83.	13.9	61
151	Whole-Exome Sequencing Reveals Defective <i>CYP3A4</i> Variants Predictive of Paclitaxel Dose-Limiting Neuropathy. <i>Clinical Cancer Research</i> , 2015, 21, 322-328.	3.2	61
152	Effects of Dietary Fat Composition on Activities of the Microsomal Ethanol Oxidizing System and Ethanol-Inducible Cytochrome P450 (CYP2E1) in the Liver of Rats Chronically Fed Ethanol. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1992, 70, 347-351.	0.0	60
153	Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1175-1179.	0.8	60
154	Induction mechanisms of cytochrome P450 2E1 in liver: Interplay between ethanol treatment and starvation. <i>Biochemical Pharmacology</i> , 1995, 50, 155-161.	2.0	59
155	Expression and Distribution of Cytochrome P450 Enzymes in Male Rat Kidney: Effects of Ethanol, Acetone and Dietary Conditions. <i>Biochemical Pharmacology</i> , 1998, 55, 123-129.	2.0	59
156	Cytokine and Chemokine Expression Associated with Steatohepatitis and Hepatocyte Proliferation in Rats Fed Ethanol via Total Enteral Nutrition. <i>Experimental Biology and Medicine</i> , 2008, 233, 344-355.	1.1	59
157	Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. <i>Glia</i> , 2007, 55, 328-340.	2.5	58
158	The past, present and future of pharmacoeigenomics. <i>Pharmacogenomics</i> , 2010, 11, 625-627.	0.6	57
159	Hepatic Differentiation and Maturation of Human Embryonic Stem Cells Cultured in a Perfused Three-Dimensional Bioreactor. <i>Stem Cells and Development</i> , 2013, 22, 581-594.	1.1	56
160	Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylation reactions catalyzed by cytochrome P-450. <i>FEBS Letters</i> , 1975, 56, 161-165.	1.3	55
161	Expression, Catalytic Activity, and Inducibility of Cytochrome P450 2E1 (CYP2E1) in the Rat Central Nervous System. <i>Journal of Neurochemistry</i> , 1996, 67, 2066-2073.	2.1	55
162	Characterization and tissue distribution of a novel human cytochrome P450—CYP2U1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 315, 679-685.	1.0	55

#	ARTICLE	IF	CITATIONS
163	The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives. <i>Archives of Toxicology</i> , 1996, 71, 45-56.	1.9	54
164	CYP1A1, GSTM1, and GSTT1 Polymorphisms, Smoking, and Lung Cancer Risk in a Pooled Analysis among Asian Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1120-1126.	1.1	54
165	DNA methylation dynamics in the hepatic CYP3A4 gene promoter. <i>Biochimie</i> , 2012, 94, 2338-2344.	1.3	54
166	Characterization of Human Cytochrome P450s Involved in the Bioactivation of Clozapine. <i>Drug Metabolism and Disposition</i> , 2013, 41, 651-658.	1.7	54
167	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017, 65, 710-721.	3.6	54
168	Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. <i>Pharmacogenetics and Genomics</i> , 1993, 3, 275-280.	5.7	53
169	A soluble NH <sub>2</sub> -terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria. <i>FEBS Letters</i> , 1999, 460, 309-314.	1.3	53
170	Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. <i>Pharmacogenomics Journal</i> , 2009, 9, 208-217.	0.9	53
171	CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 871-877.	0.8	53
172	Regulation of CYP2C19 Expression by Estrogen Receptor $\alpha$ : Implications for Estrogen-Dependent Inhibition of Drug Metabolism. <i>Molecular Pharmacology</i> , 2010, 78, 886-894.	1.0	53
173	Enzyme-Specific Transport of Rat Liver Cytochrome P450 to the Golgi Apparatus. <i>Archives of Biochemistry and Biophysics</i> , 1996, 333, 459-465.	1.4	52
174	Hepatotoxicity induced by iron overload and alcohol. <i>Journal of Hepatology</i> , 1996, 25, 538-546.	1.8	52
175	Characterization and Functional Analysis of Two Common Human Cytochrome P450 1B1 Variants. <i>Archives of Biochemistry and Biophysics</i> , 2000, 378, 175-181.	1.4	52
176	Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 259-270.	2.3	52
177	Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. <i>Toxicology in Vitro</i> , 2005, 19, 621-629.	1.1	52
178	Databases in the area of pharmacogenetics. <i>Human Mutation</i> , 2011, 32, 526-531.	1.1	52
179	Amidoxime Reductase System Containing Cytochrome b5 Type B (CYB5B) and MOSC2 Is of Importance for Lipid Synthesis in Adipocyte Mitochondria. <i>Journal of Biological Chemistry</i> , 2012, 287, 6307-6317.	1.6	52
180	Precision Medicine and Rare Genetic Variants. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 85-86.	4.0	52

#	ARTICLE	IF	CITATIONS
181	Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 65-77.	1.9	51
182	Hydroxylation of acetone by ethanol- and acetone-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. <i>FEBS Letters</i> , 1986, 196, 59-64.	1.3	50
183	High Rates of Substrate Hydroxylation by Human Cytochrome P450 3A4 in Reconstituted Membranous Vesicles: Influence of Membrane Charge. <i>Biochemical and Biophysical Research Communications</i> , 1996, 221, 318-322.	1.0	50
184	Intracellular transport and localization of microsomal cytochrome P450. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 1075-1084.	1.9	50
185	Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. <i>Pharmacogenomics</i> , 2009, 10, 1067-1076.	0.6	50
186	CYP3A4 Catalytic Activity Is Induced in Confluent Huh7 Hepatoma Cells. <i>Drug Metabolism and Disposition</i> , 2010, 38, 995-1002.	1.7	50
187	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. <i>Archives of Toxicology</i> , 2016, 90, 2979-3003.	1.9	50
188	Protein kinase C-dependent phosphorylation of profilin is specifically stimulated by phosphatidylinositol bisphosphate (PIP2). <i>Biochemical and Biophysical Research Communications</i> , 1988, 150, 526-531.	1.0	49
189	Effects of Short-Term Ethanol and Nutrition on the Hepatic Microsomal Monooxygenase System in a Model Utilizing Total Enteral Nutrition in the Rat. <i>Alcoholism: Clinical and Experimental Research</i> , 1991, 15, 693-699.	1.4	49
190	Stem Cell-Derived Systems in Toxicology Assessment. <i>Stem Cells and Development</i> , 2015, 24, 1284-1296.	1.1	49
191	Ethanol and oxidative stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	1.4	48
192	Reconstitution of the liver microsomal hydroxylase system into liposomes. <i>FEBS Letters</i> , 1977, 78, 72-76.	1.3	47
193	Rapid effects of phorbol esters on isolated rat adipocytes. Relationship to the action of protein kinase C. <i>FEBS Journal</i> , 1985, 148, 407-412.	0.2	47
194	H2O2 activates CD11b/CD18-dependent cell adhesion. <i>Biochemical and Biophysical Research Communications</i> , 1988, 157, 443-449.	1.0	47
195	Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. <i>Archives of Toxicology</i> , 1999, 73, 33-40.	1.9	47
196	Characterization of Common CYP1B1 Variants with Different Capacity for Benzo[a]pyrene-7,8-Dihydrodiol Epoxide Formation from Benzo[a]pyrene. <i>Cancer Research</i> , 2005, 65, 5105-5111.	0.4	47
197	Colon Cancer-Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins. <i>Clinical Cancer Research</i> , 2013, 19, 2952-2961.	3.2	47
198	Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. <i>Cells</i> , 2020, 9, 964.	1.8	47

#	ARTICLE	IF	CITATIONS
199	Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. <i>Biochemical Pharmacology</i> , 1996, 51, 61-69.	2.0	46
200	Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. <i>Applied in Vitro Toxicology</i> , 2018, 4, 1-12.	0.6	46
201	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , 2020, 11, 575540.	1.6	46
202	Genetic polymorphism of cytochromes P450: Interethnic differences and relationship to incidence of lung cancer. <i>Pharmacogenetics and Genomics</i> , 1992, 2, 264-271.	5.7	45
203	Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. <i>Biochemical Pharmacology</i> , 1994, 48, 1823-1833.	2.0	45
204	Generation of Mice Transgenic for Human <i>CYP2C18</i> and <i>CYP2C19</i> : Characterization of the Sexually Dimorphic Gene and Enzyme Expression. <i>Drug Metabolism and Disposition</i> , 2008, 36, 955-962.	1.7	45
205	Pharmacoepiggenetics and Toxicoepiggenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 161-185.	4.2	45
206	Induction of the ethanol-inducible form of rabbit liver microsomal cytochrome P-450 by inhibitors of alcohol dehydrogenase. <i>Biochemical and Biophysical Research Communications</i> , 1984, 124, 375-382.	1.0	44
207	Effect of chronic hypoxia on detoxication enzymes in rat liver. <i>Biochemical Pharmacology</i> , 1992, 43, 2421-2426.	2.0	44
208	Neuroprotective Agent Chlomepazine Attenuates c-fos, c-jun, and AP-1 Activation through Inhibition of p38 MAP Kinase. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 1077-1088.	2.4	44
209	Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. <i>Carcinogenesis</i> , 2003, 24, 681-687.	1.3	44
210	Transcriptional Regulation of the Human <i>CYP2A6</i> Gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 814-822.	1.3	44
211	Sex Difference in Formation of Propofol Metabolites: A Replication Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2013, 113, 126-131.	1.2	44
212	Identification and Characterization of a Mitochondrial Targeting Signal in Rat Cytochrome P450 2E1 ( <i>CYP2E1</i> ). <i>Journal of Biological Chemistry</i> , 2001, 276, 11317-11322.	1.6	43
213	In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. <i>Nucleic Acids Research</i> , 2013, 41, e72-e72.	6.5	43
214	Mechanisms of lipid peroxidation dependent upon cytochrome P-450 LM2. <i>FEBS Journal</i> , 1986, 158, 195-201.	0.2	42
215	The expression of the novel <i>CYP2W1</i> enzyme is an independent prognostic factor in colorectal cancer – A pilot study. <i>European Journal of Cancer</i> , 2009, 45, 705-712.	1.3	42
216	Epigenetic-dependent regulation of drug transport and metabolism: an update. <i>Pharmacogenomics</i> , 2012, 13, 1373-1385.	0.6	42

#	ARTICLE	IF	CITATIONS
217	Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. <i>Npj Genomic Medicine</i> , 2020, 5, 9.	1.7	42
218	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	42
219	Mechanism of rate control of the NADPH-dependent reduction of cytochrome P-450 by lipids in reconstituted phospholipid vesicles. <i>FEBS Journal</i> , 1984, 144, 509-513.	0.2	41
220	Metabolism of n-pentane by ethanol-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. <i>FEBS Journal</i> , 1986, 161, 303-308.	0.2	40
221	Requirements for comprehensive pharmacogenetic genotyping platforms. <i>Pharmacogenomics</i> , 2016, 17, 917-924.	0.6	40
222	Multiple Forms of Cytochrome P-450 in Rat-Liver Microsomes. Separation and Some Properties of Different Hydroxylases Active on Free and Sulphoconjugated Steroids. <i>FEBS Journal</i> , 1976, 64, 35-43.	0.2	38
223	Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. <i>Biochemical and Biophysical Research Communications</i> , 2005, 338, 1065-1074.	1.0	38
224	Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using <i>In Vitro</i> Models Derived from Human Embryonic Stem Cells and Human Cell Lines – A Report on the Vitrocellomics EU-project. <i>ATLA Alternatives To Laboratory Animals</i> , 2011, 39, 147-171.	0.7	38
225	Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 1991, 174, 37-42.	1.0	37
226	Oligomerization properties of ERp29, an endoplasmic reticulum stress protein. <i>FEBS Letters</i> , 1998, 431, 322-326.	1.3	37
227	Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. <i>FEBS Journal</i> , 1999, 261, 66-71.	0.2	37
228	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. <i>Toxicology in Vitro</i> , 2009, 23, 1387-1395.	1.1	37
229	A 3D Cell Culture Model Identifies Wnt/Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration. <i>Advanced Science</i> , 2020, 7, 2000248.	5.6	37
230	Colorectal Cancer-Specific Cytochrome P450 2W1: Intracellular Localization, Glycosylation, and Catalytic Activity. <i>Molecular Pharmacology</i> , 2010, 78, 1004-1011.	1.0	36
231	How to Consider Rare Genetic Variants in Personalized Drug Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 745-748.	2.3	36
232	Reduction of Cytochrome P-450 LM2 by NADPH in Reconstituted Phospholipid Vesicles is Dependent on Membrane Charge. <i>FEBS Journal</i> , 1983, 134, 157-162.	0.2	35
233	Alcoholic Liver Disease in Rats Fed Ethanol as Part of Oral or Intra-gastric Low-Carbohydrate Liquid Diets. <i>Experimental Biology and Medicine</i> , 2004, 229, 351-360.	1.1	35
234	CHARACTERIZATION AND PARTIAL PURIFICATION OF THE RAT AND HUMAN ENZYME SYSTEMS ACTIVE IN THE REDUCTION OF N-HYDROXYMELAGATRAN AND BENZAMIDOXIME. <i>Drug Metabolism and Disposition</i> , 2005, 33, 570-578.	1.7	35

#	ARTICLE	IF	CITATIONS
235	Association between CYP2C19 polymorphism and depressive symptoms. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1160-1166.	1.1	35
236	Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. Journal of Medicinal Chemistry, 2013, 56, 6273-6277.	2.9	35
237	Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. Biochemical Pharmacology, 2000, 59, 1425-1432.	2.0	34
238	Induced CYP3A4 Expression in Confluent Huh7 Hepatoma Cells as a Result of Decreased Cell Proliferation and Subsequent Pregnane X Receptor Activation. Molecular Pharmacology, 2013, 83, 659-670.	1.0	34
239	Aniline is hydroxylated by the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism. Biochemical and Biophysical Research Communications, 1982, 106, 625-631.	1.0	33
240	Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology, 2020, 45, 570-576.	2.8	33
241	Pulsatile blood alcohol and CYP2E1 induction during chronic alcohol infusions in rats. Alcohol, 1993, 10, 453-457.	0.8	32
242	A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Human Mutation, 2004, 23, 258-266.	1.1	32
243	The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Research, 2012, 32, 3869-74.	0.5	32
244	Cyclic Expression of Class I Alcohol Dehydrogenase in Male Rats Treated with Ethanol. Biochemical and Biophysical Research Communications, 2000, 274, 684-688.	1.0	31
245	Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-dimensional Spheroid Cultures of Primary Human Hepatocytes. Clinical Pharmacology and Therapeutics, 2020, 108, 844-855.	2.3	31
246	Cytochrome P-450-dependent lipid peroxidation in reconstituted membrane vesicles. Biochemical Pharmacology, 1984, 33, 2521-2523.	2.0	30
247	Cytochrome P-450-dependent oxidase activity and hydroxyl radical production in micellar and membranous types of reconstituted systems. Biochemical Pharmacology, 1988, 37, 1383-1389.	2.0	30
248	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenetics and Genomics, 2009, 19, 565-566.	0.7	30
249	High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis. Stem Cells International, 2016, 2016, 1-14.	1.2	30
250	Changes in steroid hormone metabolism in rat liver microsomes following administration of 2,3,7,8-tetrachlorodibenzo-p-dioxine (TCDD). Biochemical Pharmacology, 1979, 28, 497-499.	2.0	29
251	Differential regulation of gelatinase b and tissue-type plasminogen activator expression in human bowes melanoma cells. International Journal of Cancer, 1993, 53, 395-400.	2.3	29
252	Acetone-dependent regulation of cytochromes P4502E1 and P4502B1 in rat nasal mucosa. Biochemical Pharmacology, 1993, 46, 1945-1951.	2.0	29

#	ARTICLE	IF	CITATIONS
253	Polymorphic expression of CYP2C19 and CYP2D6 in the developing and adult human brain causing variability in cognition, risk for depression and suicide: the search for the endogenous substrates. <i>Pharmacogenomics</i> , 2014, 15, 1841-1844.	0.6	29
254	Xanthine oxidase activity is influenced by environmental factors in Ethiopians. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 533-536.	0.8	28
255	Significantly lower CYP2D6 metabolism measured as the <i>O/N</i> desmethylvenlafaxine metabolic ratio in carriers of <i>CYP2D6*41</i> versus <i>CYP2D6*9</i> or <i>CYP2D6*10</i> : a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 194-201.	1.1	28
256	A Novel CYP2C6 Haplotype Associated With Ultrarapid Metabolism of Escitalopram. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 786-793.	2.3	28
257	Specific Metabolic Pathways of Steroid Sulfates in Human Liver Microsomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1976, 43, 56-63.	1.8	26
258	Insulin-stimulated protein synthesis in adipocytes. Enhanced rate of initiation associated with increased phosphorylation of ribosomal protein S6. <i>FEBS Journal</i> , 1985, 151, 97-100.	0.2	26
259	Strong effects of environmental factors on prevalence and course of major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a large Dutch sample. <i>Journal of Affective Disorders</i> , 2013, 146, 91-99.	2.0	26
260	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 131-144.	0.7	26
261	New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4. <i>Drug Metabolism and Disposition</i> , 2010, 38, 415-421.	1.7	25
262	Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran. <i>PLoS ONE</i> , 2015, 10, e0138487.	1.1	25
263	The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 399-407.	1.0	25
264	3D human liver spheroids for translational pharmacology and toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 5-15.	1.2	25
265	The transcription factor GATA-4 regulates cytochrome P450C19 gene expression. <i>Life Sciences</i> , 2010, 86, 699-706.	2.0	24
266	[11] Spin trapping of alcohol-derived radicals in microsomes and reconstituted systems by electron spin resonance. <i>Methods in Enzymology</i> , 1994, 233, 117-127.	0.4	23
267	The Ubiquitin-Proteasome 26s Pathway in Liver Cell Protein Turnover: Effect of Ethanol and Drugs. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 225S-229S.	1.4	23
268	Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. <i>Biochemical Pharmacology</i> , 2004, 67, 1249-1258.	2.0	23
269	High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of <i>CYP2A6</i> Variant Alleles in Ethiopian Population. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 446-453.	1.0	23
270	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. <i>Archives of Toxicology</i> , 2019, 93, 385-399.	1.9	23



#	ARTICLE	IF	CITATIONS
271	Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. <i>Current Opinion in Drug Discovery &amp; Development</i> , 2010, 13, 78-85.	1.9	23
272	Neonatal androgenic programming of hepatic steroid metabolism in rats. <i>The Journal of Steroid Biochemistry</i> , 1975, 6, 643-649.	1.3	22
273	A Novel Polymorphic Cytochrome P450 Formed by Splicing of CYP3A7 and the Pseudogene CYP3AP1. <i>Journal of Biological Chemistry</i> , 2005, 280, 28324-28331.	1.6	22
274	Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1505-1512.	1.7	22
275	Intronic polymorphisms of cytochromes P450. <i>Human Genomics</i> , 2010, 4, 402.	1.4	22
276	IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. <i>Biochemical Pharmacology</i> , 2010, 80, 1592-1600.	2.0	22
277	Evaluation of the <i>CYP2D6</i> Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 750-758.	2.3	22
278	Primary human hepatocyte spheroids as an <i>in vitro</i> tool for investigating drug compounds with low clearance. <i>Drug Metabolism and Disposition</i> , 2021, , DMD-AR-2020-000340.	1.7	22
279	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004, 110, 266-270.	2.3	21
280	The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1 $\beta$ signalling but not its biosynthesis in rat cortical glial cells. <i>Journal of Neurochemistry</i> , 2002, 83, 727-737.	2.1	20
281	Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. <i>Atherosclerosis</i> , 2005, 182, 37-45.	0.4	20
282	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 241-248.	5.7	20
283	The Ligands of Estrogen Receptor $\alpha$ Regulate Cytochrome P450C9 (CYP2C9) Expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 302-309.	1.3	19
284	Mechanisms of Chronic Fialuridine Hepatotoxicity as Revealed in Primary Human Hepatocyte Spheroids. <i>Toxicological Sciences</i> , 2019, 171, 385-395.	1.4	19
285	Detection of Cytochrome P4503A (CYP3A) in Human Hepatic Stellate Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 238, 420-424.	1.0	18
286	Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors. <i>PLoS ONE</i> , 2015, 10, e0122820.	1.1	18
287	Pharmacogenomic or epigenomic biomarkers in drug treatment: Two sides of the same medal?. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 478-480.	2.3	18
288	Benzo(a)pyrene metabolism by purified forms of rabbit liver microsomal cytochrome P-450, cytochrome b5 and epoxide hydrase in reconstituted phospholipid vesicles. <i>Biochemical and Biophysical Research Communications</i> , 1980, 95, 431-439.	1.0	17

#	ARTICLE	IF	CITATIONS
289	[24] Genetic polymorphism of human cytochrome P450 2E1. <i>Methods in Enzymology</i> , 1996, 272, 218-225.	0.4	17
290	Use of Molecular Simulation for Mapping Conformational CYP2E1 Epitopes. <i>Journal of Biological Chemistry</i> , 2004, 279, 50949-50955.	1.6	17
291	Role of cytochrome P450 <i>CYP2C8*3</i> in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , 2015, 16, 929-937.	0.6	17
292	Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent. <i>Toxicology Letters</i> , 2018, 295, 187-194.	0.4	17
293	Inhibition of CYP2E1 Activity does not Abolish Pulsatile Urine Alcohol Concentrations During Chronic Alcohol Infusions. <i>FEBS Journal</i> , 1995, 230, 914-919.	0.2	17
294	Lack of sexual dimorphism in alcohol-induced liver damage (ALD) in rats treated chronically with ethanol-containing low carbohydrate diets: The role of ethanol metabolism and endotoxin. <i>Life Sciences</i> , 2004, 75, 469-483.	2.0	16
295	Activation of c-fos by lipopolysaccharide in glial cells via p38 mitogen-activated protein kinase-dependent activation of serum or cyclic AMP/calcium response element. <i>Journal of Neurochemistry</i> , 2005, 92, 915-924.	2.1	16
296	Calcium-regulating peptide hormones and blood electrolytic balance in chronic heart failure. <i>Regulatory Peptides</i> , 2007, 142, 95-100.	1.9	16
297	Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: Possible role for molecular mimicry. <i>Journal of Hepatology</i> , 2010, 53, 431-438.	1.8	16
298	The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. <i>Acta Oncologica</i> , 2014, 53, 885-891.	0.8	16
299	Pretranslational and Posttranslational Regulation of Rat Hepatic CYPs 3A2 and 2E1 by Disulfiram. <i>Biochemical Pharmacology</i> , 1997, 54, 1323-1329.	2.0	15
300	Selective Fast Degradation of Cytochrome P-450 2E1 in Serum-Deprived Hepatoma Cells by a Mechanism Sensitive to Inhibitors of Vesicular Transport. <i>FEBS Journal</i> , 1997, 247, 37-43.	0.2	15
301	Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. <i>Nucleic Acids Research</i> , 2016, 44, 6756-6769.	6.5	15
302	The CYP2W1 enzyme: regulation, properties and activation of prodrugs. <i>Drug Metabolism Reviews</i> , 2016, 48, 369-378.	1.5	15
303	Sex-specific 15 $\alpha$ -hydroxylation of sulpho-conjugated 5 $\alpha$ -androstane-3 $\beta$ , 17 $\beta$ -diol in liver microsomes from female rats. <i>FEBS Letters</i> , 1973, 31, 292-296.	1.3	14
304	In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: beyond the reduction of animal model use. <i>Drug Discovery Today</i> , 2009, 14, 401-405.	3.2	14
305	An Integrated <i>In Vitro</i> Model for Simultaneous Assessment of Drug Uptake, Metabolism, and Efflux. <i>Molecular Pharmaceutics</i> , 2013, 10, 3152-3163.	2.3	14
306	Personalized medicine into the next generation. <i>Journal of Internal Medicine</i> , 2015, 277, 152-154.	2.7	14

#	ARTICLE	IF	CITATIONS
307	The Importance of Residues in Substrate Recognition Site 3 for the Catalytic Function of CYP2D25 (Vitamin D 25-Hydroxylase). <i>Biochemical and Biophysical Research Communications</i> , 2001, 288, 1059-1063.	1.0	13
308	Qualitative Alterations of Cytochrome P450 in Mouse Liver Microsomes after Administration of Acrylamide and Methylmethacrylate. <i>Acta Pharmacologica Et Toxicologica</i> , 1978, 43, 299-305.	0.0	13
309	Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. <i>Pharmacogenomics</i> , 2018, 19, 1133-1138.	0.6	13
310	Resolution of multiple forms of phenobarbital-induced liver microsomal cytochrome P-450 by electrofocusing on granulated gels. <i>FEBS Letters</i> , 1977, 74, 103-106.	1.3	12
311	Effect of carrageenan-induced granuloma on hepatic cytochrome P-450 isozymes in rats. <i>Inflammation</i> , 1995, 19, 143-156.	1.7	12
312	Pro-inflammatory response and adverse drug reactions: Mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. <i>Toxicology in Vitro</i> , 2008, 22, 1588-1594.	1.1	12
313	Interindividual Variation in Benzo(a)pyrene Metabolism and Composition of Isoenzymes of Cytochrome P450 as Revealed by SDS-Gel Electrophoresis of Human Liver Microsomal Fractions. <i>Acta Pharmacologica Et Toxicologica</i> , 1982, 50, 251-260.	0.0	12
314	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. <i>Schizophrenia Research</i> , 2021, 228, 590-596.	1.1	12
315	The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1165-1174.	2.3	12
316	The microsomal monooxygenase system of regenerating liver. <i>Biochemical Pharmacology</i> , 1992, 43, 567-573.	2.0	11
317	Oxidoreduction of butanol in deermice ( <i>Peromyscus maniculatus</i> ) lacking hepatic cytosolic alcohol dehydrogenase. <i>FEBS Journal</i> , 1992, 204, 353-357.	0.2	11
318	Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly. <i>Archives of Biochemistry and Biophysics</i> , 2002, 408, 58-68.	1.4	11
319	Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells. <i>Stem Cells</i> , 2015, 33, 2936-2948.	1.4	11
320	Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 765-770.	4.0	11
321	The Ubiquitin-Proteasome 26s Pathway in Liver Cell Protein Turnover: Effect of Ethanol and Drugs. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 225S-229S.	1.4	11
322	Characterization of Calcium and Phospholipid Dependent Protein Kinase in Isolated Rat Adipocytes. <i>Acta Chemica Scandinavica</i> , 1985, 39b, 219-226.	0.7	11
323	Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1. <i>FEBS Letters</i> , 2016, 590, 330-339.	1.3	10
324	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , 2020, 37, 64-69.	0.3	10

#	ARTICLE	IF	CITATIONS
325	Can CYP Inhibition Overcome Chemotherapy Resistance?. Trends in Pharmacological Sciences, 2020, 41, 503-506.	4.0	10
326	Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism. Archives of Toxicology, 2021, 95, 11-25.	1.9	10
327	Protein amino acid analysis by an isotope ratio gas chromatography mass spectrometry computer technique. Biomedical Mass Spectrometry, 1979, 6, 317-324.	1.8	9
328	Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1075-1084.	2.5	9
329	<i>CYP2W1</i> polymorphism: functional aspects and relation to risk for colorectal cancer. Pharmacogenomics, 2013, 14, 1615-1622.	0.6	9
330	Translation of pharmacogenomic drug labels into the clinic. Current problems. Pharmacological Research, 2020, 153, 104620.	3.1	9
331	Dehydrogenase-dependent metabolism of alcohols in gastric mucosa of deer mice lacking hepatic alcohol dehydrogenase. Biochemical Pharmacology, 1993, 45, 1989-1994.	2.0	8
332	CYTOCHROME P450E1, HYDROXYETHYL FREE RADICALS, AND IMMUNE REACTIONS ASSOCIATED WITH ALCOHOLIC LIVER DISEASE. Alcoholism: Clinical and Experimental Research, 1998, 22, 740-742.	1.4	8
333	Liquid biopsies or therapeutic drug monitoring for <i>CYP</i> activity profile determination. Clinical Pharmacology and Therapeutics, 0, , .	2.3	8
334	Bioactivation or inactivation of toxic compounds?. Trends in Pharmacological Sciences, 1979, 1, 176-179.	4.0	7
335	Effect of <i>in Vivo</i> Chromate, Acetone and Combined Treatment on Rat Liver <i>in Vitro</i> Microsomal Chromium(VI) Reductive Activity and on Cytochrome P450 Expression. Basic and Clinical Pharmacology and Toxicology, 1991, 68, 456-463.	0.0	7
336	Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. European Journal of Clinical Pharmacology, 2012, 68, 407-413.	0.8	7
337	Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. Chemico-Biological Interactions, 2020, 325, 109131.	1.7	7
338	The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals. Pharmacogenomics Journal, 2022, 22, 247-249.	0.9	7
339	CYKI-47261, A NEW AMPA [2-AMINO-3-(3-HYDROXYMETHYLISOXAZOLE-4-YL)PROPIONIC ACID] ANTAGONIST, IS A CYP2E1 INDUCER. Drug Metabolism and Disposition, 2003, 31, 1310-1314.	1.7	6
340	Characterization of the Novel Defective CYP2C9*24 Allele. Drug Metabolism and Disposition, 2007, 35, 831-834.	1.7	6
341	Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. PLoS ONE, 2016, 11, e0162379.	1.1	6
342	Modulation of the Substrate Specificity of Purified Human Protein Kinase C by its Activators.. Acta Chemica Scandinavica, 1987, 41b, 174-179.	0.7	6

#	ARTICLE	IF	CITATIONS
343	Modulation of Oxidative Stress by Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 2005, 29, 1060-1065.	1.4	5
344	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. <i>Applied in Vitro Toxicology</i> , 2015, 1, 175-186.	0.6	5
345	Immunochemical localization and functional characterization of cytochrome P450IIE1 in rat hepatocyte foci and nodules. <i>Carcinogenesis</i> , 1991, 12, 2353-2356.	1.3	4
346	Pharmacoeigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response. <i>Expert Review of Clinical Pharmacology</i> , 2009, 2, 55-65.	1.3	4
347	Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays. <i>Toxicological Sciences</i> , 2018, 165, 4-5.	1.4	4
348	PARTIAL FEMINIZATION OF HEPATIC STEROID METABOLISM IN MALE RATS AFTER NEONATAL ADMINISTRATION OF CYPROTERONE ACETATE. <i>Journal of Endocrinology</i> , 1975, 64, 267-275.	1.2	3
349	ROLE OF CYTOCHROME P450 ENZYMES IN ALCOHOL LIVER DISEASE PATHOGENESIS. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 739-740.	1.4	3
350	What do animal experiments tell us that <i>in vitro</i> systems cannot? The Human Toxome Project. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 75, 1-4.	1.3	3
351	Genetic and environmental causes for interindividual variability in drug pharmacokinetics. <i>International Congress Series</i> , 2001, 1220, 175-186.	0.2	2
352	Integration of <i>In Vitro</i> Approaches to Predict Drug Metabolism and Interaction in Man: An EU Validation Project. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 305-306.	0.7	2
353	Institutional Profile: Karolinska Institutet. <i>Pharmacogenomics</i> , 2012, 13, 1887-1891.	0.6	2
354	CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. <i>Pharmacogenomics</i> , 2019, 20, 1085-1092.	0.6	2
355	Dynamics of Metabolic Pathways and Stress Response Patterns during Human Neural Stem Cell Proliferation and Differentiation. <i>Cells</i> , 2022, 11, 1388.	1.8	2
356	Cytochrome P450 polymorphism: From evolution to clinical use. <i>Advances in Pharmacology</i> , 2022, , .	1.2	2
357	Cytochrome P450-dependent Fragmentation of DNA in Reconstituted Membranes. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 56, 69-74.	0.0	1
358	Functional characterization of <i>CYP2D7</i> gene variants. <i>Pharmacogenomics</i> , 2018, 19, 931-936.	0.6	1
359	4th ESPT Conference: pharmacogenomics and personalized medicine – research progress and clinical implementation. <i>Pharmacogenomics</i> , 2019, 20, 1063-1069.	0.6	1
360	One non-believer: Response to ‘Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing’. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 7-8.	1.2	1

#	ARTICLE	IF	CITATIONS
361	The missing heritability in pharmacogenomics: role of NFIB and other factors. <i>Pharmacogenomics</i> , 2022, 23, 453-455.	0.6	1
362	Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937. <i>International Journal of Cancer</i> , 1988, 42, 284-288.	2.3	0
363	Inhibition of CYP2E1 Activity does not Abolish Pulsatile Urine Alcohol Concentrations During Chronic Alcohol Infusions. <i>FEBS Journal</i> , 1995, 230, 914-919.	0.2	0
364	Targeted profiling of 5-(hydroxy)methylcytosine in genomic DNA from human livers: Next-generation sequencing of target enriched DNA reveals unexpectedly high interindividual variability of cytosine methylation and hydroxymethylation. , 2014, , .		0
365	IMPACT OF CYP GENOTYPE ON THE SUCCESS OF ANTIDEPRESSANT THERAPY. <i>European Neuropsychopharmacology</i> , 2019, 29, S1030.	0.3	0
366	Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO4-9-16.	0.0	0
367	Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids. <i>Cells</i> , 2022, 11, 1597.	1.8	0